In-vitro 전사 템플릿 시장 : 제품 유형별, 질환별, 치료별, 연구 단계별, 최종 용도별 - 세계 예측

In-vitro transcription templates market size is anticipated to grow at 19.6% CAGR between 2024 and 2032, driven by advancements in molecular biology and the increasing demand for RNA-based therapeutics and diagnostics. In-vitro transcription templates play a crucial role in generating RNA molecules for research and industrial applications, including RNA vaccine development, gene expression studies, and RNA sequencing. The rise in RNA technology research, especially mRNA vaccines for infectious diseases and cancer immunotherapies, has also heightened the demand for high-quality in-vitro transcription templates.

The development of more efficient and cost-effective transcription systems, along with improved template design techniques has boosted the scalability and reproducibility of RNA production. The rising adoption of RNA-based diagnostics, especially during infectious disease outbreaks and for genetic disorders will further fuel the product demand.

The industry is segmented into product type, disease, treatment, research stage, end-use, and region.

Based on product type, the RNA templates segment is poised to grow in the in-vitro transcription templates market between 2024 and 2032. This dominance is due to its pivotal role in producing high-quality RNA for various applications, including mRNA vaccines, RNA interference therapies, and RNA diagnostics. Several scientific and medical communities are also continuing to explore and expand the applications of RNA technology, further driving the segment growth.

By disease, the in-vitro transcription templates industry from the lifestyle diseases segment is set to witness significant CAGR from 2024 to 2032. This is driven by the growing emphasis on understanding and treating diseases associated with lifestyle factors, such as diabetes, cardiovascular diseases, and obesity. These diseases often involve intricate molecular mechanisms, further necessitating gene expression analysis and RNA profiling.

Asia Pacific in-vitro transcription templates market is expected to witness notable growth from 2024 to 2032. This growth can be attributed to rapid biotechnological advancements, increased research investments, and the rising demand for RNA-based therapies and diagnostics. Moreover, countries like China, India, and Japan, with their increasing focus on personalized medicine and the rising prevalence of chronic diseases, are propelling the need for efficient RNA production methods.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in genomics and transcriptomics
    • 3.2.1.2 Increasing demand for mRNA vaccines and therapeutics
    • 3.2.1.3 Research and development in molecular biology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited accessibility and affordability
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 DNA templates
• 5.3 RNA templates
• 5.4 Templates and transcription kits
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
  • 6.2.1 Lung cancer
  • 6.2.2 Breast cancer
  • 6.2.3 Colorectal cancer
  • 6.2.4 Prostate cancer
  • 6.2.5 Leukemia
  • 6.2.6 Ovarian cancer
  • 6.2.7 Other cancers
• 6.3 Infectious disease
  • 6.3.1 Influenza
  • 6.3.2 Ebola virus
  • 6.3.3 Hepatitis C virus
  • 6.3.4 Human immunodeficiency virus (HIV)
  • 6.3.5 Dengue virus
  • 6.3.6 Other infectious diseases
• 6.4 Lifestyle disease
• 6.5 Genetic disease
• 6.6 Other diseases

Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Vaccine
• 7.3 Therapeutic

Chapter 8 Market Estimates and Forecast, By Research Stage, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Exploratory
• 8.3 Clinical

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Biotechnology and pharmaceutical companies
• 9.3 Academic and research institutes
• 9.4 Contract research organizations

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Agilent Technologies Inc.
• 11.2 Bio-Synthesis Inc.
• 11.3 Bio-Rad Laboratories Inc.
• 11.4 CINVEN LIMITED
• 11.5 Danaher Corporation
• 11.6 Enzynomics Co Ltd.
• 11.7 Enzo Biochem Inc.
• 11.8 F. Hoffmann-La Roche Ltd.
• 11.9 Illumina Inc.
• 11.10 LGC Limited
• 11.11 Merck KGaA
• 11.12 Promega Corporation
• 11.13 Qiagen N.V.
• 11.14 Takara Bio Inc.
• 11.15 Thermo Fisher Scientific Inc.